Imatinib mesylate–induced pseudoporphyria

Berghoff, Adar; English, Joseph C.

doi:10.1016/j.jaad.2010.01.060

Cited by 15 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imatinib has been reported to cause both precipitation and reactivation of PCT . Curiously, imatinib has also been implicated in causing pseudoporphyria . Imatinib‐induced photosensitivity and hypopigmentation appears to play a role in its causation .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…18,19 Curiously, imatinib has also been implicated in causing pseudoporphyria. 20,21 Imatinibinduced photosensitivity and hypopigmentation appears to play a role in its causation. 21 Vesicobullous lesions over acral parts were seen in 12 (2.7%) patients.…”

Section: Discussionmentioning

confidence: 99%

Long‐term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…reported two cases of porphyria cutanea tarda induced or reactivated by imatinib treatment (the serum porphyrin levels returned to normal and cutaneous lesions resolved on discontinuation of therapy) . A case of pseudoporphyria induced by imatinib has been described too . Drummond et al .…”

Section: Imatinib Mesylatementioning

confidence: 99%

“…67,68 A case of pseudoporphyria induced by imatinib has been described too. 69 Drummond et al first reported a case of graft-versus-host disease-like reaction and small-vessel vasculitis, 13 whereas Hamm et al 70 and Breccia et al 54 noted purpuric vasculitis after imatinib use. Battistella et al 71 and Bos et al 72 have reported only two cases of hand-foot skin reaction.…”

Section: Imatinib Mesylatementioning

confidence: 99%

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience

Brazzelli

Grasso

Borroni

2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

In the last years, several tyrosine kinase inhibitors (TKIs) have been developed and approved for human cancer treatment. Imatinib mesylate was the first of this novel family of drugs that target cancer-specific molecules and signalling pathways. The appearance of imatinib resistances led to the introduction of second-generation TKIs with higher potency and selectivity, such as dasatinib and nilotinib. However, the range of activity of these agents is not simply directed at tumour cells. Patients and their clinicians are indeed frequently confronted with the cutaneous side-effects associated with the employ of these drugs, which represent the most common non-hematological adverse reactions. For this reason, a systematic dermatological survey of patients receiving these therapies is highly important, and an early and appropriate dermatological treatment is required. In this review, we analyse the clinical and pathological characteristics of the most commonly reported adverse skin events associated with first- and second-generation tyrosine kinase inhibitors, with a particular emphasis on our clinical experience.

show abstract

“…2 There have also been reports of pseudoporphyria induced by tyrosine kinase inhibitors (TKIs), such as imatinib, in which C-kit inhibition has been ascribed a mechanistic role. [3][4][5][6] No cases of sunitinib-induced pseudoporphyria have been described to date.…”

Section: Sunitinib-induced Pseudoporphyriamentioning

confidence: 99%